ERG and neoplasm: Immune checkpoint inhibitors also represent a potential therapeutic avenue for ERG+/PTEN+ tumours, as this subtype may maintain a more immunologically active tumour microenvironment compared to PTEN-deficient subtypes, though the efficacy of these treatments remains under research (105, 106).